Rafiq Nabi

Rafiq Un Nabi

Assistant Professor (Research)

Department of Pathobiological Sciences

LSU School of Veterinary Medicine
Louisiana State University
Baton Rouge, LA 70803

EMAIL DR. NABI

Education

PhD, Louisiana State University Health Sciences Center (New Orleans), 2017

MSc, University of Dhaka, Bangladesh, 2010

BSc University of Dhaka, Bangladesh, 2008

Research Interest

Mechanism of vaccine mediated protection at mucosal surface.

Oncolytic virotherapy in solid tumor.

Teaching Interest

Viral pathogenesis

Awards & Honors

Phi Zeta Research Emphasis Day, Post-doctoral Category

Publications

Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With γδT Cell Intracorneal Infiltration. 10.3389/fimmu.2021.789454

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity. DOI: 10.3390/vaccines9070774

Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Mode. 10.1128/JVI.01359-20

Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. 10.1172/jci.insight.126047

Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. 10.1371/journal.pone.0228252

The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. 10.1002/jmv.25985